Poor
Mostly Unaligned
Patient Risk:
Low
Summary
The provided FDA label excerpts address ocular toxicity, eye-care/premedication, monitoring, and ocular dose modifications. The AI-generated claims supplied here largely concern treatment duration, pricing/insurance, and comparative/market-access assertions that are not supported by the provided prescribing information excerpts, resulting in many unsupported statements. No contradictions with the provided excerpts were identified because the excerpts do not cover those topics.
Category Scores
Accurate Statements
Tivdak can cause severe ocular adverse reactions, including conjunctivitis, keratopathy/keratitis, and dry eye, that may lead to changes in vision and/or corneal ulceration; requires ophthalmic exams and adherence to premedication/eye care; dose withholding/reduction/discontinuation guidance based on severity/persistence.
Supported by the provided excerpts from Sections 5.1, 2.2, 2.3, and patient counseling in 17.
Unsupported Statements
A course of Tivdak typically lasts about 6–8 weeks.
The provided prescribing information excerpts do not state a typical course length or duration of therapy.
In the United States, a course of Tivdak runs around $48,000.
The provided prescribing information excerpts do not contain pricing or cost figures.
Most commercial insurers and Medicare Part D plans list Tivdak as an in-network drug.
The provided prescribing information excerpts do not discuss formulary status or insurer network coverage.
Out-of-pocket cost for Tivdak can still be significant even when it is in-network.
The provided prescribing information excerpts do not address patient cost-sharing outcomes.
Copays and coinsurance for Tivdak depend on the specific insurance plan.
The provided prescribing information excerpts do not address copay/coinsurance mechanics.
Patients may qualify for manufacturer assistance programs that reduce their share of Tivdak costs.
The provided prescribing information excerpts do not mention manufacturer assistance programs.
The price of Tivdak is set by the manufacturer.
The provided prescribing information excerpts do not address price-setting responsibility.
Tivdak pricing reflects the drug’s development costs, clinical trial data, and market demand.
The provided prescribing information excerpts do not provide any rationale for pricing.
Tivdak can be used for advanced cervical cancer and other solid tumors.
The provided prescribing information excerpts do not include an FDA-approved indication statement for these uses.
The cost of a course of Tivdak in Canada is reported as roughly CAD 60,000.
The provided prescribing information excerpts do not contain Canada pricing/cost figures.
CAD 60,000 for a Tivdak course in Canada translates to about $46,000 USD.
The provided prescribing information excerpts do not include currency conversion or pricing.
Compared with bevacizumab, Tivdak’s price is roughly double for a comparable duration of treatment.
The provided prescribing information excerpts do not provide comparative pricing with bevacizumab.
Tivdak has a different mechanism of action than bevacizumab.
The provided prescribing information excerpts do not discuss mechanisms of action for Tivdak or bevacizumab.
Tivdak can be effective in patients who have progressed on other lines of therapy.
The provided prescribing information excerpts do not provide efficacy claims or line-of-therapy language.
Patients can sometimes secure discounts through manufacturer patient-assistance programs.
The provided prescribing information excerpts do not mention patient-assistance discounts.
Pharmacy benefit manager (PBM) negotiations can sometimes reduce Tivdak costs.
The provided prescribing information excerpts do not address PBM negotiations.
Tivdak costs are often paid through a combination of insurance, out-of-pocket, and manufacturer rebates.
The provided prescribing information excerpts do not mention rebates or payment composition.
In some cases, hospitals negotiate bulk pricing or use PBM agreements to lower the net cost of Tivdak.
The provided prescribing information excerpts do not address hospital bulk pricing or PBM agreements.
The current price of Tivdak is set for the next 12–24 months.
The provided prescribing information excerpts do not address the duration of price-setting or timing.
The price of Tivdak may change if the manufacturer introduces a new pricing strategy.
The provided prescribing information excerpts do not address potential price changes.
The price of Tivdak may change if regulatory changes affect reimbursement.
The provided prescribing information excerpts do not discuss reimbursement-driven price changes.
Contradictions
Important Omissions
If the AI response intended to discuss ocular risk management, it should include label-mandated specific eye-care/premedication steps and monitoring schedule details (e.g., corticosteroid drop regimen timing/duration, vasoconstrictor immediate use, cold packs, lubricating drops duration, and contact lens avoidance) and dose modification criteria. These details are not present in the provided list of claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported safety content in the supplied material relates to ocular toxicity (a boxed warning/warning topic in the excerpts). Most other claims concern pricing/insurance and do not directly alter clinical safety instructions within the provided excerpts; however, the absence of detailed ocular management instructions in the supplied claims could contribute to incomplete safety communication if those topics were meant to be clinically instructional.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Majority of claims (course duration and all pricing/insurance/market-access statements and several indication/efficacy/mechanism statements) are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Limit assertions to content explicitly present in the provided label excerpts (ocular adverse reaction risk, monitoring/exam schedule, required premedication/eye care, and ocular dose modification/discontinuation). Remove or qualify pricing/insurance and other non-label claims unless the full FDA label text addressing those topics is provided.